These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 13216835)

  • 1. Clinical features of genetic variants of sickle cell disease.
    CONLEY CL; SMITH EW; KING JT
    Trans Assoc Am Physicians; 1954; 67():261-7. PubMed ID: 13216835
    [No Abstract]   [Full Text] [Related]  

  • 2. Modifier genes and sickle cell anemia.
    Steinberg MH; Adewoye AH
    Curr Opin Hematol; 2006 May; 13(3):131-6. PubMed ID: 16567954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical features of the genetic variants of sickle cell disease.
    SMITH EW; CONLEY CL
    Bull Johns Hopkins Hosp; 1954 Jun; 94(6):289-318. PubMed ID: 13160682
    [No Abstract]   [Full Text] [Related]  

  • 4. Phenotype/genotype relationships in sickle cell disease: a pilot twin study.
    Weatherall MW; Higgs DR; Weiss H; Weatherall DJ; Serjeant GR
    Clin Lab Haematol; 2005 Dec; 27(6):384-90. PubMed ID: 16307540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. University students in Nigeria: knowledge, attitude toward sickle cell disease, and genetic counseling before marriage.
    Moronkola OA; Fadairo RA
    Int Q Community Health Educ; 2006-2007; 26(1):85-93. PubMed ID: 17686716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics of morphine: Potential implications in sickle cell disease.
    Darbari DS; Minniti CP; Rana S; van den Anker J
    Am J Hematol; 2008 Mar; 83(3):233-6. PubMed ID: 17722074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Genetic modifiers of homozygous sickle cell disease].
    Hartmann K; Kulozik AE
    Klin Padiatr; 2006; 218(3):170-3. PubMed ID: 16688674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diagnosis and screening of sickle cell disease].
    Wajcman H
    Rev Prat; 2004 Sep; 54(14):1543-7. PubMed ID: 15558963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining stroke risks in sickle cell anemia.
    Meschia JF; Pankratz VS
    Nat Genet; 2005 Apr; 37(4):340-1. PubMed ID: 15800645
    [No Abstract]   [Full Text] [Related]  

  • 10. Sickle cell disease: a multigenic perspective of a single gene disorder.
    Kutlar A
    Hemoglobin; 2007; 31(2):209-24. PubMed ID: 17486504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Sickle cell disease pathophysiology: from theoretical to practical aspects].
    Galactéros F
    Rev Prat; 2004 Sep; 54(14):1534-42. PubMed ID: 15558962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of the G-463A myeloperoxidase polymorphism with infection in sickle cell anemia.
    Costa RN; Conran N; Albuquerque DM; Soares PH; Saad ST; Costa FF
    Haematologica; 2005 Jul; 90(7):977-9. PubMed ID: 15996936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy.
    Hebbel RP; Osarogiagbon R; Kaul D
    Microcirculation; 2004 Mar; 11(2):129-51. PubMed ID: 15280088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensinogen gene associated polymorphisms and risk of stroke in sickle cell anemia: Additional data supporting an association.
    Romana M; Diara JP; Doumbo L; Muralitharan S; Ramasawmy R; Keclard L; Tarer V; Chaar V; Elion J; Krishnamoorthy R; Clayton J
    Am J Hematol; 2004 Jul; 76(3):310-1. PubMed ID: 15224377
    [No Abstract]   [Full Text] [Related]  

  • 15. The dilemma of defining clinical severity in homozygous sickle cell disease.
    Serjeant GR
    Curr Hematol Rep; 2004 Sep; 3(5):307-9. PubMed ID: 15341695
    [No Abstract]   [Full Text] [Related]  

  • 16. Molecular analysis of Iranian families with sickle cell disease.
    Ayatollahi M; Zakerinia M; Haghshenas M
    J Trop Pediatr; 2005 Jun; 51(3):136-40. PubMed ID: 15831669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Extensive bone marrow necrosis as presenting manifestation of sickle cell disease in Africa].
    Simon F; Carloz E; Chaudier B; Kraemer P; Colbacchini P; Hovette P
    Med Trop (Mars); 2004; 64(2):179-82. PubMed ID: 15460150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
    Italia K; Jain D; Gattani S; Jijina F; Nadkarni A; Sawant P; Nair S; Mohanty D; Ghosh K; Colah R
    Blood Cells Mol Dis; 2009; 42(1):25-31. PubMed ID: 18954999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of RANTES and MBL2 gene polymorphisms in sickle cell disease clinical outcomes: association of the g.In1.1T>C RANTES variant with protection against infections.
    Dossou-Yovo OP; Zaccaria I; Benkerrou M; Hauchecorne M; Alberti C; Rahimy MC; Elion J; Lapoumeroulie C
    Am J Hematol; 2009 Jun; 84(6):378-80. PubMed ID: 19425063
    [No Abstract]   [Full Text] [Related]  

  • 20. [Sickle cell disease in heel injection screening. II].
    Vansenne F; de Borgie CA; Bouva MJ; Legdeur MA; van Zwieten R; Petrij F; Peters M
    Ned Tijdschr Geneeskd; 2009 May; 153(18):858-61. PubMed ID: 19475864
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.